free counter

Bill Gates Is Reupping His Commitment To Alzheimers Research And Detection

For Bill Gates, donating toward Alzheimer’s research and detection is both personal and practical. His father experienced Alzheimer’s disease. And his philanthropic investment team determined that better diagnostics may help advance treatment.

AFP via Getty Images

Four years back, Bill Gates led an attempt where he and some other billionaires, including Jeff Bezos and MacKenzie Scott, pledged $30 million to produce a new engine in a Alzheimers foundation to increase development of tests which could diagnose the condition. That funding later grew to $50 million.

Now the Alzheimers Drug Discovery Foundation has announced a fresh $50 million funding commitment from previous donors including Gates, Bezos, former Estee Lauder chair Leonard Lauder and the household of the late Ray Dolby in addition to some new donorsmoney which will support the next thing of its efforts to really improve detection of Alzheimers disease. (Lauder founded the building blocks along with his brother Ronald Lauder.) The donations to the Alzheimers Drug Discovery Foundation are venture philanthropy. Any financial returns that the investments receive will return back in to the foundation, instead of in to the pockets of any donors.

Gates, Bezos and Lauder are actually each donating $11.25 million toward the foundations diagnostics effort, while Dolby Family Ventures is contributing $5 million. The four new donors joining them to aid diagnostics research will be the drug companies Biogen (donating $5 million) and Eli Lilly & Co. (donating $1 million), the NFL Players Association and the Shanahan Family Charitable Foundation, that is donating $5 million and is linked with former Capital Group executive R. Michael Shanahan, who, per his obituary, died in 2020 following a long struggle with Alzheimers disease.

The donation by Bill Gates is personal aswell. In January 2018, he revealed on the Today show that his then 92-year-old father, Bill Gates Sr., experienced Alzheimers disease. Bill Gates Sr. died in 2020 at age 94.

Alzheimers has been difficult to diagnose. As Gates spelled out in a post in 2018, neither of both most typical methodsa spinal tap or perhaps a PET scanare ideal. A spinal tap is invasive and will be uncomfortable, and a PET scan requires patients to sit very still so long as 40 minutes, which isnt an easy task to do.

The target for the Alzheimers Drug Discovery Foundations diagnostics effort would be to have accessible non-invasive tests as an eye scan or blood tests which could perform an early on diagnosis of the condition. Some already are in developmentand a fresh blood test for research purposes was announced by way of a foundation-backed company called Quanterix on Wednesday.

The role of our philanthropy would be to take risks, says Dr. Howard Fillit, cofounder and Chief Science Officer of the Alzheimers Drug Discovery Foundation. The seed capital we offer is critically important. Fillit describes the task that the building blocks does as funding the valley of deathhelping shepherd promising academic research into pre-clinical trialsresearch that’s often viewed as too risky by many venture capitalists and by big pharma.

Niranjan Bose, managing director for health insurance and life sciences at Bill Gates investment firm Gates Ventures, explains that with the foundations first $50 million diagnostics fund in 2018, we started seeding the [diagnostics] field with investments. Now some of these investments have advanced to the stage where they want more funding, and perhaps, bigger checks of $2 million to $3 million. So Gates among others are re-upping their donations now, says Bose, to obtain those sprouts to keep growing.

Fillit, who in addition has been treating patients with Alzheimers disease for 40 years, brims with enthusiasm concerning the progress that is made up to now. When he first started working as a health care provider, the only method to diagnose Alzheimers was with a brain biopsy (following the patient had died). At this time I could send an individual for a brain scan called Amyvid that’s FDA-approved, he say. That scan, he adds, can simply tell him with 90% certainty whether an individual gets the disease. The Alzheimers Drug Discovery Foundation seed funded Amyvid, that was initially produced by Avid Radiopharmaceuticals and researchers at the University of Pennsylvania; now it really is owned by Eli Lily & Co.

Its a thrilling time for Alzheimers researchers. You can find a lot more than 120 drugs in clinical trials all over the world; 30 of these have obtained funding from the Alzheimers Drug Discovery Foundation. In the last four years, the foundations diagnostics accelerator has invested about $50 million in a lot more than 40 global studies offering blood tests, eye scans and early digital technology.

An organization called RetiSpec, backed partly by the building blocks, is creating a retinal test that detects neurodegenerative changes. The attention may be the window to the mind, explains Fillit, who envisions a scenario where you might choose your eye checkup one per year and also have extra imaging performed which could detect Alzheimers disease less invasively than current tests do.

Bose of Gates Ventures can be keen on the chance of an ocular test to diagnose Alzheimersbecause it might detect the condition earlier. Before you begin seeing amyloid [proteins linked with Alzheimers] in the blood, you start to see it in the rear of the retina, says Bose, who estimates that maybe it’s another couple of years prior to the retinal test will be ready. Others are pursuing optical diagnostic tests aswell.

For anybody interested in how exactly to push away Alzheimers given the existing insufficient easy diagnosis and having less drugs that halt the condition, Fillit says much has been learned all about prevention. The essential premise is whats best for your heart is wonderful for the human brain, he explains, pointing to regular physical exercise; a Mediterranean diet; avoiding smoking, alcohol and stress; and getting enough sleep. The building blocks website has information regarding prevention and also reviews foods and supplements and articles on brain health.

There’s still much to understand about Alzheimers disease and related dementias. Fillit says research on the condition is maybe 50 years behind where our knowledge of cancer is. One challenge: Its difficult and expensive to sign up patients in Phase 3 clinical trials for new Alzheimers treatments. But having better diagnostics will make that process better and much less costly, says Fillit. And better diagnostics could enable enrolling patients into trials at a youthful stage of the condition.

Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker